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Abstract
Beta-blockers are used to treat acquired heart failure in adults, though their role in early muscular dystrophy
cardiomyopathy is unclear. We treated 2 different dystrophic mouse models which have an associated cardiomyopathy
(mdx: model for Duchenne Muscular Dystrophy, and Sgcd-/-: model for limb girdle muscular dystrophy type 2F) and wild
type controls (C57 Bl10) with the beta blocker metoprolol or placebo for 8 weeks at an early stage in the development of
the cardiomyopathy. Left and right ventricular function was assessed with cardiac magnetic resonance imaging (MRI) and
in-vivo myocardial calcium influx with manganese enhanced MRI. In the mdx mice at baseline there was reduced stroke
volume, cardiac index, and end-diastolic volume with preserved left ventricular ejection fraction. These abnormalities were
no longer evident after treatment with beta-blockers. Right ventricular ejection fraction was reduced and right ventricular
end-systolic volume increased in the mdx mice. With metoprolol there was an increase in right ventricular end-diastolic and
end-systolic volumes. Left and right ventricular function was normal in the Sgcd-/- mice. Metroprolol had no significant
effects on left and right ventricular function in these mice, though heart/body weight ratios increased after treatment. In-
vivo myocardial calcium influx with MEMRI was significantly elevated in both models, though metoprolol had no significant
effects on either. In conclusion, metoprolol treatment at an early stage in the development of cardiomyopathy has
deleterious effects on right ventricular function in mdx mice and in both models no effect on increased in-vivo calcium
influx. This suggests that clinical trials need to carefully monitor not just left ventricular function but also right ventricular
function and other aspects of myocardial metabolism.
Citation: Blain A, Greally E, Laval S, Blamire A, Straub V, et al. (2013) Beta-Blockers, Left and Right Ventricular Function, and In-Vivo Calcium Influx in Muscular
Dystrophy Cardiomyopathy. PLoS ONE 8(2): e57260. doi:10.1371/journal.pone.0057260
Editor: German E. Gonzalez, University of Buenos Aires, Cardiovascular Pathophysiology Institute, Argentina
Received October 4, 2012; Accepted January 22, 2013; Published February 20, 2013
Copyright:  2013 Blain et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funded in part by Heart Research UK grant RG 2585 and British Heart Foundation Clinical Leave Research Fellowship FS/11/89/29162 (both to GMG).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: guy.macgowan@nuth.nhs.uk
Introduction
In Duchenne muscular dystrophy the absence of dystrophin
causes subclinical or clinical dilated cardiomyopathy [1,2]. Also,
mutations in one of the genes for a-, b-, c- or d-sarcoglycan, a
heterogeneous group of autosomal recessive limb girdle muscular
dystrophies (LGMD2C-F), cause severe dilated cardiomyopathy at
a young age in addition to muscular dystrophy, especially in those
patients with LGMD2F caused by mutations in the d-sarcoglycan
gene [1–3].
Beta-blockers are established treatments for acquired heart
failure [4] though the role in inherited cardiomyopathies is less
clear. It has been suggested that for certain dystrophin mutations
which predispose to cardiomyopathy, early treatment including
beta-blockers is of benefit [5]. We have shown that in mdx mice,
which lack the protein dystrophin as in Duchenne muscular
dystrophy that there are benefits in terms of left ventricular
pressure-volume derived data with early beta- blocker treatment,
though detrimental effects in the delta sarcoglycan deficient mouse
model (Sgcd-/-, model for limb girdle muscular dystrophy type 2F)
[6]. This suggests that not all underlying genotypes may respond
beneficially to beta-blockers.
However, left ventricular pressure and volume measurements
are not the only physiological measurements that can assess the
effects of a systemic treatment. Right ventricular function is
frequently abnormal in cardiomyopathy. Both left and right
ventricular function can be assessed non-invasively with cardiac
magnetic resonance imaging (MRI). Increased intracellular
calcium is an important feature of muscular dystrophy cardiomy-
opathy and plays a central role in its pathophysiology [7].
Manganese-enhanced magnetic resonance imaging (MEMRI) can
assess in-vivo calcium influx using 2 properties of the manganese
ion [8]. Manganese enters cardiomyocytes through calcium
channels, and is also a T1 contrast agent with MRI. Thus,
manganese influx results in a relative increase in contrast-
enhancement on T1 weighted images.
The purpose of this study was to treat 2 different mouse models
of muscular dystrophy cardiomyopathy with beta-blockers at an
early stage in the development of the cardiomyopathy to
determine if there are beneficial effects on left and right ventricular
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function and to determine whether beta-blockers reduced in-vivo
myocardial calcium influx.
Materials and Methods
Animals
Male mdx (n = 15) from Jackson laboratories (Bar Harbor, ME,
USA), Sgcd-/- mice (n = 11) and C57 Bl10 mice (Jackson
Laboratories) (n = 6) were treated with metoprolol and compared
to age matched controls (mdx (n = 21), Sgcd-/- (n = 20), C57 Bl10
(n = 19)). Mice were housed under controlled temperature (17–
28uC) and light conditions (12:12h light: dark cycle). Animals had
free access to food and water. The investigations conformed with
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health [NIH Publication No.85–
23, revised in 1985 and was performed under the terms of the
Animals (Scientific Procedures) Act 1986, authorized by the Home
Secretary, Home Office UK]. All experiments were performed at
the animal care facility of Newcastle University, UK. The work
was approved by the Ethical Review Committee of Newcastle
University.
Drug treatment
Metoprolol (2.5 mg/kg/day) (M5391, Sigma-Aldrich) was
administered orally via the drinking water, which was refreshed
every 48 hours. From our previous studies [9–11] we have been
able to establish that mice (housed under the conditions in our
animal unit) drink an average volume of 2.5 ml/day drinking
water. Mice were weighed fortnightly and the concentration of
metoprolol in the drinking water was adjusted accordingly.
Treatment was initiated in the mdx mice at 16 weeks and at
8 weeks in the Sgcd-/- mice, timepoints which are early in the
development of left ventricular dysfunction [12]. Treatment was
continued for 8 weeks and cardiac function was assessed in the mdx
mice at 24 weeks of age and 16 weeks in Sgcd-/- mice; ages at
which cardiac function has previously been shown to be impaired
in these mouse models [6,10]. The C57 Bl10 mice were aged
12 weeks at the start of the treatment as an intermediate age
between the mdx and Sgcd-/- mice.
MRI
Following induction of anaesthesia with 5% isofluorane in an
anaesthetic chamber, mice were cannulated via the tail vein and
laid prone on a cradle that allowed monitoring of body
temperature, respiratory rate and heart rate heart rate (Dazai
Research Instruments, Toronto, Canada). Mice were placed in the
magnet and anaesthesia was maintained using 1–1.8% isofluorane
via a nose cone. Their body temperature was maintained using a
warm air blower. Images were acquired on a 7 Tesla horizontal
bore Varian microimaging system equipped with a 12-cm
microimaging gradient insert (maximum gradient 40 gauss/cm),
(Varian Inc., Palo Alto, CA, USA). Mice were scanned in a
39 mm diameter quadrature birdcage volume coil (Rapid
Biomedical GmbH). Following power calibration and global
shimming a series of four pilot transverse images were acquired
over the heart. Single slice coronal and sagittal images were then
obtained in order to view the apex and mitral valve planes. These
images were used to plan for the true short axis plane. To measure
ventricular function, up to twelve contiguous short axis slices were
acquired to cover the entire left and right ventricles using a spoiled
gradient-echo cine sequence (TR=5 ms, TE= 1.42 ms, flip angle
15u, FOV 30630 mm, data matrix 1286128, 1 mm slice
thickness). Images were ECG triggered to the R wave with a cine
delay of 15 ms and typically 30 phases were acquired distributed
through the cardiac cycle. Images were zero-filled to a matrix size
of 2566256. Scans were converted to matfiles using a matlab
script (kindly provided by Johannes Riegler, UCL) and analysed
using the freely available analysis software Segment v1.8 (http://
segment.heiberg.se) to give LV and RV functional parameters.
Segment automatically delineated the endocardial and pericardial
borders at end systole and end diastole and manual adjustments
were made if necessary. LV mass, RV and LV volumes, ejection
fractions and cardiac output were calculated.
Manganese enhanced MRI (MEMRI)
Manganese chloride (60 mM, Sigma-Aldrich 244589) was given
by intravenous infusion through the tail vein canula at a flow-rate
of 0.6 ml/hour. Flow time was adjusted according to weight to
give a total dose of 190 nmol/g body weight (for example, for a
30 g mouse, this would result in a 9.5 minute infusion). Single slice
gradient echo short axis images at the level of the papillary muscles
(T1 weighted parameters: TR=35 ms, TE= 3.5 ms, flip angle
60u, FOV 30 mm630 mm, data matrix 1286128, 1 mm slice
thickness, 6 averages) were taken. Prior to manganese infusion four
baseline images were acquired in order to average any variations
due to changes in TR as a result of fluctuations in heart rate.
Infusion was begun and images were taken at 2.5 mins, 5 mins
and then at 5 minute intervals thereafter, for 30 minutes. A
relative increase in T1 weighted contrast indicates increased
manganese uptake. The time course stack of images were analysed
in ImageJ (http://rsb.info.nih.gov/ij). An area of interest was
drawn to fit inside the myocardium and average signal intensity
was measured. If necessary, minor adjustments of this drawn
region were made for subsequent images in the stack and the
increase in myocardial contrast enhancement was expressed as a
percentage increase from the average of the four baseline images
(which showed little or no variation). MEMRI data is expressed as
an enhancement ratio over baseline.
Statistics
Where appropriate, data was normalized to body weight. All
data are reported as mean 6 [standard error]. Differences
between animal and treatment groups were compared by
univariate general linear model ANOVA with Bonferroni-Sidak
posthoc testing, and statistically significant findings of P,0.05 are
reported.
Results
Ventricular hypertrophy in untreated mdx mice and
metoprolol-treated Sgcd-/- mice
Metoprolol treatment was well tolerated and there were no early
deaths in the treated mice. Sgcd-/- mice had lower body weights
compared to C57 Bl10 controls (table 1). Compared to untreated
C57 Bl10 mice, mdx mice had evidence of ventricular hypertrophy
(post mortem combined weight of right and left ventricles) with
elevated heart to body weight ratios with and without metroprolol,
and the Sgcd-/- mice had an increased heart to body weight ratio
after metroprolol only (table 1). Mean anesthetized heart rates for
all groups are shown in Figure 1a.
In mdx mice metoprolol has beneficial effects on left ventricular
size and function though detrimental effects on right ventricular
size, whilst in Sgcd-/- mice metroprolol increases left ventricular
size
C57 Bl10.. Beta-blockers had no significant effects on left or
right ventricular function or left ventricular mass.
Mdx.. The cardiomyopathy in the untreated mdx mice was
characterized by a smaller left ventricular cavity in diastole,
Beta-Blockers in Muscular Dystrophy Cardiomyopathy
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e57260
reduced stroke volume and cardiac output although left ventric-
ular mass (determined by MR imaging) and left ventricular
ejection fraction were not significantly different from controls
(Figures 1b and 2). Metoprolol had beneficial effects on left
ventricular function in mdx; stroke volume index (Figure 2a), end-
diastolic left ventricular volume index (Figure 2a) and cardiac
output index (Figure 2c) were all normalized towards C57 Bl10
values. Right ventricular dysfunction was not significantly
improved by treatment however. Mdx mice have marked right
ventricular dysfunction with reduced right ventricular ejection
fraction and increased right ventricular end-systolic volume at
baseline (Figure 3, and 4a and b). Metoprolol did not normalize
these parameters and indeed there was a further increase in right
ventricular end-diastolic volume such that this parameter was now
significantly higher than C57 Bl10 and Sgcd-/- controls, and right
ventricular end-systolic volume was significantly higher than
metoprolol-treated C57 Bl10 mice (Figure 4b).
Sgcd-/-.. The untreated Sgcd-/- mice had normal left and
right ventricular systolic function and left ventricular mass when
compared with C57 Bl10 controls (Figures 1 and 2). There was
some evidence of change in left ventricular function in the Sgcd-/-
mice with metoprolol; in addition to the increased heart weight to
body weight ratio (Table 1), the left ventricular end-diastolic, end-
systolic and stroke volume indexes (Figure 2a) were significantly
increased compared to untreated mdx mice, though not compared
to C57 Bl10 mice. There were no significant changes in right
ventricular function with metoprolol (Figure 4).
Metoprolol treatment does not normalize increased in-
vivo calcium influx in mdx or Sgcd-/- mice as measured by
MEMRI
There were no significant effects of beta-blocker treatment on
the C57 Bl10 mice on manganese influx. Manganese influx was
increased in both mdx and Sgcd-/- mice compared to C57 Bl10
mice at early (5 – 15 minutes) and steady state (10 – 25 minutes)
stages following the start of the infusion (p,0.05, ANOVA) (Figure
5 a-d) as previously demonstrated [13], indicating in-vivo increased
calcium influx occurring at an early stage in the development of
the cardiomyopathy. This was not significantly affected in either
group by treatment with metoprolol (p = ns, ANOVA).
Discussion
In two mouse models of muscular dystrophy cardiomyopathy
treated with the beta-blocker metoprolol at an early stage in the
development of the cardiomyopathy, we show that there are
differences in left and right ventricular function and the responses
to treatment. In the mdx mice without treatment there is
ventricular hypertrophy, reduced left ventricular stroke volume
with a small left ventricular cavity size, normal left ventricular
ejection fraction but reduced right ventricular ejection fraction.
Consistent with our previous invasive catheter based studies there
are benefits of metroprolol on left ventricular function in the mdx
mice, but here we also demonstrate deterioration in right
ventricular function. The Sgcd-/- mice develop ventricular
hypertrophy with metoprolol (compared to untreated C57 Bl10
mice), but have normal left and right ventricular function without
treatment with no significant effects of treatment on left or right
ventricular function relative to C57 Bl10 mice. Despite these
heterogeneous patterns of ventricular function in the 2 models,
both exhibit increased intracellular calcium influx that is
unaffected by metoprolol. Thus, overall responses to metoprolol
in both models are largely either absent or potentially detrimental.
Figure 1. Heart rates and left ventricular mass to body weight
ratio. (A) Mean anesthetized heart rates in all groups; (BPM=beats/
min, – sign indicates without metoprolol and + indicates with). (B) Left
ventricular mass to body weight ratio as determined by MR imaging is
not affected by metoprolol treatment (LVM= left ventricular mass,
BW=body weight, – sign indicates without metoprolol and + indicates
with).
doi:10.1371/journal.pone.0057260.g001
Table 1. Body and heart weights of metoprolol treated mice.
C57 Bl10 C57Bl10 metoprololSgcd-/- Sgcd-/- metoprolol Mdx mdx metoprolol
Body weight (g) 32.6 (0.72) 31.7 (0.76) 29.3 (0.63) * 29.1 (0.53) * 35.6 (0.55) 33.2 (1.08) $$
Heart weight (mg) 125.8 (2.73) 132.0 (6.94) 131.6 (3.95) 143.2 (4.70) 156.4 (4.30)*** $$ 151.8 (6.53) *
Heart weight to body
weight ratio
3.9 (0.12) 4.2 (0.26) 4.4 (0.13) 4.9 (0.09) *** 4.4 (0.09)* 4.5 (0.14) *
Mean+SEM. * different from C57 B10 control, $ different from Sgcd-/- control. Number of symbols denotes level of significance e.g. *p,0.05, **p,0.01, ***p,0.001
doi:10.1371/journal.pone.0057260.t001
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Right ventricular function
In clinical heart failure, right ventricular dysfunction is an
important predictor of outcomes [14]. In muscular dystrophy
cardiomyopathy, right ventricular dysfunction may be an impor-
tant early feature. In Becker’s muscular dystrophy cardiac
involvement appears to develop first in the right ventricle when
seen in younger patients, and left ventricular involvement develops
at a later age [15,16]. In the mdx mouse model, right ventricular
dysfunction has also been shown to be an important early feature,
and similarly to the clinical studies above, right ventricular
dysfunction precedes left ventricular dysfunction [17]. This
suggests that the pathophysiology of right ventricular dysfunction
is due to an intrinsic right ventricular process as opposed to right
ventricular dysfunction developing secondary to left ventricular
dysfunction in the setting of secondary pulmonary hypertension
and increased right ventricular afterload. The detrimental effect of
metroprolol on this early marker of cardiomyopathy in the mdx
mice would suggest caution for early beta-blocker usage. One
potential explanation linking the apparent improvement in left
ventricular function and deterioration in right ventricular function
is that the relatively low stroke volume from the left ventricle
without treatment protects the abnormal and susceptible right
ventricle from excessive volume overload. However, the beta-
blockers restore stroke volume and cardiac output to wild type
levels and this increased flow to the right side of the heart then
causes greater dilatation of the right ventricle. This is a
phenomenon that is well recognized when patients with biven-
tricular dysfunction have left ventricular output restored with a left
ventricular assist device that then aggravates right ventricular
dysfunction [18].
Figure 2. Effect of metoprolol treatment on left ventricular function. (A) Left ventricular volume to body weight (BW) ratios; (B) Ejection
fraction; (C) Cardiac output (CO) to body weight ratio. Reductions in left ventricular end-diastolic and (LV EDV) and left ventricular stroke volume
index (LV SV) in untreated mdx mice were no longer evident after metoprolol treatment. In untreated Sgcd-/- mice there was normal left ventricular
function, and after treatment with metropolol there were increases in end-diastolic, end-systolic (LV ESV) and stroke volume indexes relative to
untreated mdx mice. (*different from C57 Bl10 control, $different from Sgcd-/- control,ˆdifferent from mdx control; number of symbols denotes level of
significance e.g. *p,0.05, **p,0.01, ***p,0.001); (– sign indicates without metoprolol and + indicates with).
doi:10.1371/journal.pone.0057260.g002
Figure 3. Mdx mice have RV dilatation. Representative 2 chamber
short axis cine slices at the level of the papillary muscles (basal to apical
slices from left to right) at end diastole in mdx and C57 Bl10 mice. The
right ventricle is highlighted in blue in the first slices.
doi:10.1371/journal.pone.0057260.g003
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Left ventricular function and mass
Whereas our findings with respect to left ventricular function
and beta-blockade in these models are similar to those that we
have found with pressure volume loop based conductance catheter
studies (especially in the mdx mouse), there are clearly differences
between the 2 methods [6]. Stroke volume was reduced with the
conductance catheter study in the Sgcd-/- mice, though is
unaffected in the current study relative to C57 Bl10 mice. There
are several potential reasons for this. Firstly, a different anaesthetic
regimen was previously used (fentanyl, fluanisone and midazolam
i.p.) as opposed to isoflurane in the current study, and it is known
that different anaesthetic agents can have markedly different
effects on cardiac function [19]. Also, the conductance catheter is
an invasive procedure which involves some blood loss and an
abdominal incision for the inferior vena caval occlusions. Heart
rates tended to be higher with the conductance catheter study. In
general, as previously recognised, left ventricular volumes are
much lower when measured with the conductance catheter [20–
21]. There are however unique aspects of both of these techniques
that make them both useful: MRI allows for assessment of right
ventricular function and other aspects of metabolism such as
calcium influx with MEMRI; whereas the conductance catheter
allows for analysis of pressure-related measurements such as dP/
dtmax and min and pressure-volume calculations of left ventricular
contractility. Finally, it is possible that the two methods have
different sensitivities to detect subtle changes in ventricular
volumes. There are potential discrepancies in the ex-vivo measure-
ments of heart to body weight ratios and the MRI measurements
of left ventricular mass. The heart to body weight ratio involves
both right and left ventricles, and with the dilatation of the right
ventricle in the mdx mouse this is a plausible reason why left
ventricular mass is not increased, although heart to body weight
ratio is. In the Sgcd-/- mice the heart to body weight ratio increases
after metoprolol, and this may be reflected in the higher left
ventricular volumes relative to untreated mdx mice after metopro-
lol treatment, and is consistent with our previous conductance
catheter studies in these mice with metoprolol showing deterio-
ration in systolic and diastolic function.
In-vivo myocardial calcium influx
Increased calcium influx into the cardiac myocyte is an
important phenomenon in muscular dystrophy cardiomyopathy
leading to progression of left ventricular dysfunction. Recurrent
membrane injury leads to an increased influx of calcium [22]
which then causes downstream effects such as activation of
calcium-dependent hypertrophic pathways [23], reactive oxygen
species [24] and cell death through necrosis with mitochondrial
defects [25]. MEMRI can be used to non-invasively assess
myocardial calcium influx [8], and we have recently shown that
it is increased in these 2 mouse models [13]. Despite the similar
increase in calcium influx in both models we showed that there
were likely different mechanisms responsible for this in the 2
models. In the Sgcd-/- mice there was less reduction in contrast
enhancement with the L-type calcium channel blocker diltiazem
compared to the mdx or wild type mice. Also, higher heart rates
played some role in the increased contrast enhancement in the
Sgcd-/- mice, though heart rate was seen not to account for all the
increase when this was brought down to wild type levels. The
current study suggests that this important pathophysiological
mechanism leading to left ventricular dysfunction is unaffected by
beta-blockade. We do not know if successful treatment with beta-
blockers in situations where it is proven that they have beneficial
effects on outcomes (such as adult heart failure) reduces calcium
influx, and so the exact relevance of this finding pending further
studies is unclear.
Conclusions
Treatment with the beta-blocker metoprolol at an early stage in
the development of the cardiomyopathy leads to worsening right
ventricular function in the mdx mouse, and in both models has no
effect on calcium influx. This suggests that clinical studies with
beta-blockers and other heart failure medications should compre-
hensively evaluate not only left ventricular function but also right
ventricular function and other aspect of myocardial metabolism.
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Figure 4. Deterioration in right ventricular function with
metoprolol in mdx mice. Right ventricular ejection fraction (RV EF,
panel A), and right ventricular volume data (with abbreviations as for LV
in figure 2, panel B). (*Different from C57 Bl10 control, $different from
Sgcd-/- control, #different from metoprolol-treated C57 Bl10, number of
symbols denotes level of significance e.g. *p,0.05, **p,0.01,
***p,0.001); (BW=body weight, – sign indicates without metoprolol
and + indicates with).
doi:10.1371/journal.pone.0057260.g004
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